The biotech mergers and acquisitions market faces significant headwinds in the first half of 2025. These challenges include frozen capital markets, regulatory uncertainty at the Food and Drug Administration (FDA) and...more
4/22/2025
/ Acquisitions ,
Biotechnology ,
Capital Markets ,
Department of Health and Human Services (HHS) ,
Financial Distress ,
Food and Drug Administration (FDA) ,
Mergers ,
Pharmaceutical Industry ,
Regulatory Requirements ,
Reverse Mergers ,
Shareholder Activism
On March 25, 2025, the Delaware General Assembly enacted amendments to the Delaware General Corporation Law (the DGCL and such amendments, the DGCL Amendments), which were subsequently signed into law by the governor of...more
With companies constantly developing new therapies and technologies, the biotech industry is a hotbed of innovation. This dynamic environment often leads to mergers and acquisitions (M&A) as a vehicle for larger companies to...more